Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Schlumberger NV (SLB) Price & Performance

Abeona Therapeutics IncTrade
Schlumberger NVTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Schlumberger NV — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Schlumberger NV trades at $53.7 (market cap $78.96B). The key difference: Schlumberger NV is far larger — about 186.1× Abeona Therapeutics Inc's market cap, and Schlumberger NV pays a 2.22% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOSLB
Market Cap
$424.33M$78.96B
Sector
HealthEnergy
52-Week High
$7.45$58.01
52-Week Low
$4.17$31.72
Enterprise Value
$279.23M$87.68B
Dividend Yield
2.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Schlumberger NV

SLB's stock trades at $50.53, down 1.96% over the past day, but maintains a bullish technical signal with strong moving average support. The company recently reported Q2 2026 earnings of $0.55 per share, beating estimates, and has a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53% and a P/E ratio of 24.65.

The outlook for SLB is positive, driven by growth in offshore, digital, and production segments, though risks include Middle East volatility and net debt levels. With 85% of analysts rating it a buy and a dividend yield supported by recent payments, the stock presents a compelling opportunity for investors seeking energy sector exposure with solid fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Schlumberger NV

Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.

Read more on SLB